Drug Profile

Research programme: Huntington's disease therapeutics - CHDI/Ionis Pharmaceuticals/KineMed

Alternative Names: ISIS 387898; ISIS 388241; ISIS 408737

Latest Information Update: 04 Nov 2017

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Isis Pharmaceuticals
Developer Ionis Pharmaceuticals
Class Antisense oligonucleotides
Mechanism of Action Protein synthesis inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Huntington's disease

Most Recent Events

04 Nov 2017 No recent reports of development identified for preclinical development in Huntington's-disease in USA (Parenteral)
18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
19 May 2014 CHDI and KineMed extend their collaboration for Huntington's disease therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com